Sano Genetics

Sano Genetics's mission is to accelerate the future of personalised medicine. The software platform connects patients directly with biotech and pharma, accelerating research on rare, chronic diseases.

First Year of Investment 2022
Type of Investment Early Stage
Investment Status Current
Investment Lead Charlotte Barttelot

Sano has developed a software platform that connects patients living with rare and chronic conditions, such as long Covid, multiple sclerosis, Parkinson’s and Alzheimer’s, directly with biotech and pharmaceutical companies with the aim to develop personalised treatments more quickly and at a lower cost. There is no cost to participants, who use at-home DNA kits to take part.

Sano Genetics operates a subscription model, charging its pharmaceutical, biotech, and population health clients for use of its platform. The company also offers its biotech and pharmaceutical clients the ability to power branded portals for participant recruitment and engagement, on a national or global scale.

Newsletter Sign Up

Sign up for latest news